THE PRIMER

Patient advocacy groups are the campaign managers of medicine—mobilizing support, raising funds, pushing policy, and even influencing which drugs are developed. They're often founded by passionate patients or families and have become a powerful force in shaping the...

Drug names sound like someone dropped the alphabet—adalimumab, omeprazole, atorvastatin—but these tongue-twisters are coded. The FDA (along with other naming bodies) uses a system of prefixes, infixes, and suffixes to sneak in info about what the generic drug is, what...

The National Institutes of Health (NIH) has been the quiet powerhouse fueling America’s biomedical research engine. With a hefty annual budget ($47 billion in 2025), NIH funds everything from basic biology to life-saving therapies, making it a critical player in...

Pharmaceutical commercialization is like the ultimate relay race: it takes groundbreaking science and sprints it across the finish line to improve lives.

Ever wonder where biotech start-ups get their big, bold ideas? Biotech innovation often starts in academic labs—usually funded partially by the National Institutes of Health (NIH).

Working professionals in exciting, dynamic industries like biotech, pharma, and med device have much to gain by keeping up with the latest technologies, best practices, and scientific techniques.

Continuing professional education (CPE) courses offer an edge, enabling life science financial professionals to keep pace with innovations, advance their careers, and sharpen in-demand skills.

Antisense oligonucleotide (ASO) technology revolutionizes disease treatment by specifically targeting and modifying RNA. This therapeutic class is rapidly gaining traction due to its precision in targeting proteins that are inaccessible to traditional treatments.